Mainz Biomed (QUCY) Competitors

Cadrenal Therapeutics presently has a consensus price target of $13.00, suggesting a potential upside of 105.70%. Given Cadrenal Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Cadrenal Therapeutics is more favorable than Mainz Biomed.

In the previous week, Cadrenal Therapeutics had 5 more articles in the media than Mainz Biomed. MarketBeat recorded 5 mentions for Cadrenal Therapeutics and 0 mentions for Mainz Biomed. Cadrenal Therapeutics' average media sentiment score of 0.03 beat Mainz Biomed's score of 0.00 indicating that Cadrenal Therapeutics is being referred to more favorably in the media.

Cadrenal Therapeutics has a beta of 1.81, suggesting that its stock price is 81% more volatile than the S&P 500. Comparatively, Mainz Biomed has a beta of 0.42, suggesting that its stock price is 58% less volatile than the S&P 500.

7.9% of Cadrenal Therapeutics shares are owned by institutional investors. 26.1% of Cadrenal Therapeutics shares are owned by company insiders. Comparatively, 9.8% of Mainz Biomed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Mainz Biomed's return on equity of 0.00% beat Cadrenal Therapeutics' return on equity.

Cadrenal Therapeutics has higher earnings, but lower revenue than Mainz Biomed. Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Cocrystal Pharma has a consensus price target of $6.00, suggesting a potential upside of 334.78%. Given Cocrystal Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Cocrystal Pharma is more favorable than Mainz Biomed.

In the previous week, Cocrystal Pharma had 1 more articles in the media than Mainz Biomed. MarketBeat recorded 1 mentions for Cocrystal Pharma and 0 mentions for Mainz Biomed. Mainz Biomed's average media sentiment score of 0.00 equaled Cocrystal Pharma'saverage media sentiment score.

Mainz Biomed has a beta of 0.42, meaning that its share price is 58% less volatile than the S&P 500. Comparatively, Cocrystal Pharma has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500.

6.7% of Cocrystal Pharma shares are owned by institutional investors. 9.8% of Mainz Biomed shares are owned by insiders. Comparatively, 28.1% of Cocrystal Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Mainz Biomed's return on equity of 0.00% beat Cocrystal Pharma's return on equity.

Cocrystal Pharma has lower revenue, but higher earnings than Mainz Biomed. Cocrystal Pharma is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

In the previous week, Mainz Biomed's average media sentiment score of 0.00 equaled Anebulo Pharmaceuticals'average media sentiment score.

Anebulo Pharmaceuticals has lower revenue, but higher earnings than Mainz Biomed. Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Mainz Biomed's return on equity of 0.00% beat Anebulo Pharmaceuticals' return on equity.

Mainz Biomed has a beta of 0.42, suggesting that its share price is 58% less volatile than the S&P 500. Comparatively, Anebulo Pharmaceuticals has a beta of -1.93, suggesting that its share price is 293% less volatile than the S&P 500.

28.4% of Anebulo Pharmaceuticals shares are held by institutional investors. 9.8% of Mainz Biomed shares are held by insiders. Comparatively, 80.6% of Anebulo Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Anebulo Pharmaceuticals has a consensus price target of $3.00, indicating a potential upside of 552.17%. Given Anebulo Pharmaceuticals' higher probable upside, analysts plainly believe Anebulo Pharmaceuticals is more favorable than Mainz Biomed.

Lipocine has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500. Comparatively, Mainz Biomed has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500.

Lipocine has higher revenue and earnings than Mainz Biomed. Lipocine is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

In the previous week, Lipocine had 1 more articles in the media than Mainz Biomed. MarketBeat recorded 1 mentions for Lipocine and 0 mentions for Mainz Biomed. Lipocine's average media sentiment score of 0.00 equaled Mainz Biomed'saverage media sentiment score.

Lipocine currently has a consensus price target of $15.00, indicating a potential upside of 543.78%. Given Lipocine's stronger consensus rating and higher probable upside, research analysts plainly believe Lipocine is more favorable than Mainz Biomed.

9.1% of Lipocine shares are held by institutional investors. 6.4% of Lipocine shares are held by company insiders. Comparatively, 9.8% of Mainz Biomed shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Mainz Biomed has a net margin of 0.00% compared to Lipocine's net margin of -487.00%. Mainz Biomed's return on equity of 0.00% beat Lipocine's return on equity.